These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38665038)

  • 41. Comment on: Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.
    Vicenzi P; Ray A
    Pediatr Blood Cancer; 2021 Apr; 68(4):e28776. PubMed ID: 33089615
    [No Abstract]   [Full Text] [Related]  

  • 42.
    Mastropolo R; Close A; Allen SW; McClain KL; Maurer S; Picarsic J
    Blood Adv; 2019 Jun; 3(12):1848-1853. PubMed ID: 31213430
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis.
    Goyal G; Abeykoon JP; Hu M; Young JR; Shah MV; Bennani NN; Call TG; Hook CC; Pardanani A; Inwards DJ; Vassallo R; Ryu JH; Tobin WO; Koster MJ; Davidge-Pitts CJ; Ravindran A; Rech KL; Go RS;
    Am J Hematol; 2021 May; 96(5):E146-E150. PubMed ID: 33539584
    [No Abstract]   [Full Text] [Related]  

  • 44. Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition.
    Awada G; Seremet T; Fostier K; Everaert H; Neyns B
    Blood Adv; 2018 Aug; 2(16):2156-2158. PubMed ID: 30154124
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.
    Messinger YH; Bostrom BC; Olson DR; Gossai NP; Miller LH; Richards MK
    Pediatr Blood Cancer; 2020 Dec; 67(12):e28712. PubMed ID: 32991018
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical challenges in a patient with two BRAF V600E-mutated diseases.
    Willenbacher E; Willenbacher W; Loeffler-Ragg J
    Thorax; 2019 Jun; 74(6):620-622. PubMed ID: 30661020
    [No Abstract]   [Full Text] [Related]  

  • 47. Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations.
    Pina-Oviedo S; Medeiros LJ; Li S; Khoury JD; Patel KP; Alayed K; Cason RC; Bowman CJ; Yin CC
    Mod Pathol; 2017 May; 30(5):734-744. PubMed ID: 28084334
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
    Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
    J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation.
    Hervier B; Haroche J; Arnaud L; Charlotte F; Donadieu J; Néel A; Lifermann F; Villabona C; Graffin B; Hermine O; Rigolet A; Roubille C; Hachulla E; Carmoi T; Bézier M; Meignin V; Conrad M; Marie L; Kostrzewa E; Michot JM; Barete S; Taly V; Cury K; Emile JF; Amoura Z;
    Blood; 2014 Aug; 124(7):1119-26. PubMed ID: 24894769
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Langerhans cell histiocytosis of the stomach with BRAF-V600E-mutation: case report and review of the literature].
    Sarbia M; Mauerer R; Bettstetter M; Funk A
    Z Gastroenterol; 2015 Apr; 53(4):302-5. PubMed ID: 25860580
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inflammatory serum cytokines and chemokines increase associated with the disease extent in pediatric Langerhans cell histiocytosis.
    Morimoto A; Oh Y; Nakamura S; Shioda Y; Hayase T; Imamura T; Kudo K; Imashuku S;
    Cytokine; 2017 Sep; 97():73-79. PubMed ID: 28582647
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Incidental Langerhans cell histiocytosis of the colon with
    Cortazar JM; Kim AS
    Blood; 2017 Oct; 130(16):1870. PubMed ID: 29051154
    [No Abstract]   [Full Text] [Related]  

  • 53. Pulmonary Langerhans cell histiocytosis: profiling of multifocal tumors using next-generation sequencing identifies concordant occurrence of BRAF V600E mutations.
    Yousem SA; Dacic S; Nikiforov YE; Nikiforova M
    Chest; 2013 Jun; 143(6):1679-1684. PubMed ID: 23287985
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Success of Trametinib in the Treatment of Langerhans Cell Histiocytosis With Novel MAPK Pathway Mutations.
    Orr K; Hustak S; Beaudoin R; Ray A
    J Pediatr Hematol Oncol; 2023 May; 45(4):e534-e538. PubMed ID: 36730444
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis.
    Zarnegar S; Durham BH; Khattar P; Shukla NN; Benayed R; Lacouture ME; Lavi E; Lyden DC; Diamond EL; Dunkel IJ; Abdel-Wahab O
    Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28748614
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy.
    Aricò M
    Br J Haematol; 2016 Jun; 173(5):663-70. PubMed ID: 26913480
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis.
    Parekh D; Lin H; Batajoo A; Peckham-Gregory E; Karri V; Stanton W; Scull B; Fleishmann R; El-Mallawany N; Eckstein OS; Prudowsky ZD; Gulati N; Agrusa JE; Ahmed AZ; Chu R; Dietz MS; Goldman SC; Hogarty MD; Imran H; Intzes S; Kim JM; Kopp LM; Levy CF; Neff P; Pillai PM; Sisk BA; Schiff DE; Trobaugh-Lotrario AD; Walkovich K; McClain KL; Allen CE
    Br J Haematol; 2024 May; 204(5):1888-1893. PubMed ID: 38501389
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of Multifocal Multisystem BRAF Positive Langerhans Cell Histiocytosis with Cladribine, Surgery and Allogenic Stem Cell Transplantation.
    Gabalec F; Šimkovič M; Zavřelová A; Kašparová P; Morávková P; Kopáčová M; Masopust V; Žák P; Čáp J; Radocha J
    Acta Medica (Hradec Kralove); 2017; 60(4):152-156. PubMed ID: 29716681
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An effective treatment in Erdheim Chester disease: vemurafenib: a case report.
    Bozan E; Darçın T; Yaman S; Yiğenoğlu TN; Kızıl Çakar M; Dal MS; Altuntaş F
    J Med Case Rep; 2023 Oct; 17(1):426. PubMed ID: 37821987
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cellular morphology of BRAF V600E-positive Langerhans cell histiocytosis.
    Satpathy AT; Tan BT
    Blood; 2015 Oct; 126(15):1857. PubMed ID: 26734696
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.